Mepsgen Co., Ltd.

MEPSGEN is a biotech company that develops microengineered physiological systems called organ-on-a-chip and uses the manufactured systems to study new drug development. The company carries out fundamental biological research in an environment equipped with an organ-level function of connected human tissues instead of in a traditional in-vitro experimental model using 2D cell culture. MEPSGEN’s platform is intended to create an innovative human model-centered drug. The company was founded in 2019 by YongTae Kim and Robert Langer.
According to PitchBook, MEPSGEN’s latest deal type was Series A and the latest deal amount was $2.53M. The company has one investor. MEPSGEN’s primary industry is drug discovery.